Orexo AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1995-01-01
- Employees
- 116
- Market Cap
- -
- Website
- http://www.orexo.se
Clinical Trials
15
Active:9
Completed:5
Trial Phases
4 Phases
Phase 1:3
Phase 3:2
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (37.5%)Phase 3
2 (25.0%)Phase 4
2 (25.0%)Not Applicable
1 (12.5%)OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
Not Applicable
Completed
- Conditions
- Opioid-use Disorder
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 437
- Registration Number
- NCT04948307
- Locations
- 🇺🇸
Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸North County Clinical Research, Oceanside, California, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults
Phase 3
Completed
- Conditions
- Opioid Dependence, on Agonist Therapy
- Interventions
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 759
- Registration Number
- NCT01908842
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
Phase 4
Completed
- Conditions
- Opioid Dependence, on Agonist Therapy
- Interventions
- Drug: Higher bioavailability BNX sublingual tablets
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 668
- Registration Number
- NCT01903005
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Phase 3
Completed
- Conditions
- Opioid-Related DisordersOpiate Dependence
- Interventions
- First Posted Date
- 2013-05-07
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 313
- Registration Number
- NCT01848054
Conversion From Fast Acting Oral Opioids to Abstral®
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Orexo AB
- Target Recruit Count
- 8
- Registration Number
- NCT01315886
- Locations
- 🇸🇪
Smärtavdelning B42, Anestesikliniken Karolinska University Hospital, Huddinge, Stockholm, Sweden
News
Orexo's OX640 Nasal Epinephrine Shows Rapid Absorption in Allergic Rhinitis Study
Orexo AB announced positive topline results from a clinical study of OX640, a nasal rescue medication for allergic reactions, including anaphylaxis.